U.K. Secures 30 Million Doses of Coronavirus Vaccine Candidate From Pfizer and BioNTech

If Pfizer's (NYSE: PFE) mRNA-based coronavirus vaccine candidate ends up coming to market, it will find a ready customer in the U.K. government.

The pharmaceutical giant and its partner, Germany-based BioNTech (NASDAQ: BNTX), announced Monday that they signed a deal with the country to supply 30 million doses of the vaccine. This is pending success in clinical trials and approval from the relevant regulators.

Pfizer and BioNTech did not provide the financial details of the arrangement, but did say that its terms depend on timing and volume of doses.

Continue reading

Source Fool.com